Prognosis of HER2 expression in cholangiocarcinoma when evaluated using gastric cancer methodology of immunohistochemistry.

Fernandes, Viviane Teodoro Oliveira; Barros, Milton; Begnami, Maria D.; Saito, Augusto Obuti

doi:10.1200/jco.2015.33.15_suppl.e15203

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has reported that HER2 overexpression is an independent prognostic factor in CCA. 35 However, in our study HER2 expression alone did not affect survival outcome but, when combined with IgG for OV, HER2 expression in the OV IgG positive group had a significantly poor outcome. In the same way, combined non-intraductal type with IgG for OV positive cases also has poor outcomes, As OV-associated CCA is a very aggressive type of bile duct cancer with extremely poor survival outcomes, further comprehensive studies should be undertaken to determine which treatment strategies are effective against this type of CCA.…”

Section: Discussioncontrasting

confidence: 68%

Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression

Titapun

Techasen

Sa-Ngiamwibool

et al. 2020

IJGM

View full text Add to dashboard Cite

Background: Serum antibody for Opisthorchis viverrini (OV) is strong evidence for a history of OV infection in people. Currently, no studies have examined whether varying cholangiocarcinoma (CCA) prevalence levels are linked to previous OV infection nor have they provided comprehensive assessment and characterization of OV-associated CCA. Objective: Our study examined the prevalence of serum IgG antibodies for OV-positive CCA cases and determined whether there were correlations of IgG antibodies with histopathologic features, HER2, PD-L1, and FGFR2 expression, as well as their roles on the patients' survival. Methods: The study involved 221 CCA surgical patients at

show abstract

Section: Discussioncontrasting

confidence: 68%

Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression

Titapun

Techasen

Sa-Ngiamwibool

et al. 2020

IJGM

View full text Add to dashboard Cite

show abstract

“…With a frequency of approximately 1.4%, this study demonstrates that HER2 gene amplification is in fact a rare event in CCA. The reported frequencies for HER2 positivity vary strongly with most studies being conducted in Asia or Southern America [29–37]. Until today, only five investigations on HER2 positivity have been carried out in Europe [13, 14, 16, 18, 20].…”

Section: Discussionmentioning

confidence: 99%

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

et al. 2019

View full text Add to dashboard Cite

BackgroundCholangiocarcinoma is a rapidly fatal cancer entity with a median survival of less than one year. In contrast to many other malignancies, no substantial therapeutic breakthrough has been made in the past few decades, thereby limiting the treatment to cytotoxic chemotherapy with little beneficial effect for most patients. Targeted therapy tailored to the individual has shown substantial success in the recent past as a promising avenue for cancer therapy.MethodsIn this study, we determined the frequency of amplification of the HER2 gene in a comprehensive and well-characterized European cholangiocarcinoma cohort encompassing 436 patients including intrahepatic (n = 155), proximal (n = 155) and distal (n = 126) cholangiocarcinoma by strict application of a combined immunohistochemical and in situ hybridization algorithm following the current guidelines for HER2 assessment in gastric cancer.ResultsWe identified a proportion of 1.4% (n = 6) patients that demonstrated HER2 gene amplification, with the highest rate among the distal cholangiocarcinoma patients (2.4%). None of the patients with equivocal (2+) immunohistochemical staining results exhibited gene amplification molecularly. In four of the five patients with HER2 positivity, gene amplification was already present in concomitantly tested high-grade biliary intraepithelial neoplasia (80%). HER2 gene amplification was not significantly associated with other clinical parameters, including survival.ConclusionsThis study identifies HER2 gene amplification as a rare event in cholangiocarcinoma of the Western population, occurring already in high-grade BilIN in a subset of patients. Furthermore, we provide a robust testing algorithm that may be used prior to therapy administration in future clinical trials evaluating the role of HER2 as a predictive marker in cholangiocarcinoma.

show abstract

“…In an interesting and large study [ 74 ], HER2 amplification was found in 1.4% of more than 400 surgically resected and histologically confirmed CCAs. More variable results have been reported in South American or Asian populations [ 75 , 76 , 77 , 78 , 79 ] (from 0.1% to 20%). These differences are likely attributable to the remarkable inconsistency in HER2 testing methods used so far.…”

Section: Her2 Amplification In Ccamentioning

confidence: 85%

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology

Capuozzo

Santorsola

Landi³

et al. 2022

IJMS

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a malignant neoplasm arising in the epithelium of the biliary tract. It represents the second most common primary liver cancer in the world, after hepatocellular carcinoma, and it constitutes 10–15% of hepatobiliary neoplasms and 3% of all gastrointestinal tumors. As in other types of cancers, recent studies have revealed genetic alterations underlying the establishment and progression of CCA. The most frequently involved genes are APC, ARID1A, AXIN1, BAP1, EGFR, FGFRs, IDH1/2, RAS, SMAD4, and TP53. Actionable targets include alterations of FGFRs, IDH1/2, BRAF, NTRK, and HER2. “Precision oncology” is emerging as a promising approach for CCA, and it is possible to inhibit the altered function of these genes with molecularly oriented drugs (pemigatinib, ivosidenib, vemurafenib, larotrectinib, and trastuzumab). In this review, we provide an overview of new biologic drugs (their structures, mechanisms of action, and toxicities) to treat metastatic CCA, providing readers with panoramic information on the trajectory from “old” chemotherapies to “new” target-oriented drugs.

show abstract

Prognosis of HER2 expression in cholangiocarcinoma when evaluated using gastric cancer methodology of immunohistochemistry.

Cited by 7 publications

References 0 publications

<p>Serum IgG as a Marker for <em>Opisthorchis viverrini</em>-Associated Cholangiocarcinoma Correlated with HER2 Overexpression</p>

<p>Serum IgG as a Marker for <em>Opisthorchis viverrini</em>-Associated Cholangiocarcinoma Correlated with HER2 Overexpression</p>

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology

Contact Info

Product

Resources

About